Increased iron and oxidative stress have been heavily  implicated in the  neurodegenerative process in Parkinson’s. The removal of excess iron through iron chelation represents a potentially exciting drug target for Parkinson's.  

Dr David Devos has led a Europe-wide consortia of neurologists and Parkinson’s specialists to secure funding from the EU’s Horizon 2020 programme to run a clinical trial through 28 centres across Europe to understand the efficacy of Deferiprone, an iron-chelator in the treatment of people with Parkinson’s.

‘The Cure Parkinson’s Trust is supporting this important trial as Deferiprone was prioritised in 2012 by our Linked Clinical Trials Committee, so seeing this potentially valuable treatment come forward into trial is wonderful.’ 

Dr Richard Wyse - Research & Development Director-CPT

Sixty patients within the study will also be asked to use the SENSE-PARK objective measurement system, which The Cure Parkinson’s Trust helped to develop between 2011 and 2014.

There are three recruiting centres within the UK, and recruitment is underway. If you would like to find out more about the Fair Park II trial, please click here.